Using the HistoSonics Edison System to treat pancreatic cancer

The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using Histotripsy

This study is testing a new treatment using the HistoSonics Edison System to see if it can safely destroy tumors in patients with advanced pancreatic cancer that can't be removed by surgery.

Quick facts

• Phase: NA
• Study type: Interventional
• Enrollment: 50 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: HistoSonics, Inc. (industry)
• Drugs / interventions: chemotherapy, immunotherapy, radiation
• Locations: 1 site (Barcelona)
• Trial ID: NCT06282809 on ClinicalTrials.gov

What this trial studies

This trial evaluates the safety of the HistoSonics Edison System, which utilizes histotripsy to destroy pancreatic adenocarcinoma tumors. It is a prospective, multi-center, single-arm feasibility trial focusing on patients with unresectable locally advanced (Stage 3) or oligometastatic (Stage 4) pancreatic cancer. Participants will undergo imaging within 36 hours post-procedure and will be followed up at multiple time points to assess safety and efficacy.

Who should consider this trial

Good fit: Ideal candidates are adults aged 18 and older with unresectable pancreatic adenocarcinoma who have received chemotherapy and have a good performance status.

Not a fit: Patients with resectable pancreatic tumors or those who have not received prior chemotherapy may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a non-invasive option for patients with advanced pancreatic cancer who are not surgical candidates.

How similar studies have performed: While the approach of using histotripsy is innovative, similar studies have shown promise in other tumor types, but this specific application is relatively novel.

Eligibility criteria

Inclusion Criteria:

1. Subject is ≥18 years of age.
2. Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
3. Subject is diagnosed with unresectable pancreatic adenocarcinoma (locally advanced \[Stage 3\] or oligometastatic disease \[Stage 4\]) confirmed via CT or MR imaging ≤14 days prior to the planned index procedure.

   NOTE: If Stage 4 disease, there must be ≤5 metastatic tumors, the tumors must be located only in the liver and/or lung, and the metastatic tumors must be stable.
4. Subject is not a surgical candidate and has received chemotherapy ≥8 weeks.
5. Subject can tolerate general anesthesia.
6. Subject has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) grade 0-1 at baseline.
7. Subject meets the following criteria ≤14 days prior to the planned index procedure date:

   * Hemoglobin ≥ 9 g/dL,
   * Neutrophil count \>1.0 x 10\^9/L,
   * Platelet \>50 x 10\^9/L,
   * Total bilirubin ≤2.5x Institutional Upper Limit of Normal (IULN),
   * Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5x IULN,
   * International Normalized Ratio (INR) value \<1.5,
   * Serum creatinine \<2.0mg/dL or an estimated glomerular filtration rate (eGFR) ≥45mL/min.
8. The targeted pancreatic tumor is ≥2 cm in longest diameter.
9. The planned histotripsy treatment volume is ≥1.0 cm from any portion of the duodenum, small intestine, stomach, or colon as visualized on ultrasound, and CT, or MR imaging.
10. Subject has an adequate acoustic window to visualize targeted tumor using the HistoSonics Edison System.
11. Subject will undergo histotripsy treatment of only one (1) tumor during the index procedure, regardless of how many tumors are present in the pancreas.

Exclusion Criteria:

1. Subject is pregnant or planning to become pregnant or nursing (lactating) during the trial period.
2. Subject has had prior pancreatic, bilioenteric, or gastric surgery.
3. Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
4. Subject has an uncorrectable coagulopathy.
5. Subject has a life expectancy of less than six (6) months.
6. Subject has a biliary or pancreatic stent and/or percutaneous biliary tube that encompasses the planned histotripsy treatment volume.
7. Subject has metastases to organs other than the liver and/or lung (e.g., bone, brain, peritoneum).
8. Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
9. Subject has an active duodenal or gastric ulcer requiring medical management.
10. Subject is undergoing active chemotherapy for any cancer ≤7 days prior to planned index procedure date.\*
11. Subject is undergoing active immunotherapy or targeted therapies ≤30 days prior to planned index procedure date.
12. Subject's targeted tumor has had prior locoregional therapy (e.g., ablation, embolization, or radiation).
13. Subject has a planned cancer treatment (e.g., pancreatic surgery, targeted therapy, immunotherapy) exclusive of chemotherapy, ≤30 days post index procedure.
14. Subject has planned chemotherapy ≤14 days post index procedure.\*
15. Subject has not recovered (CTCAE grade 2 or better) from chemotherapy or immunotherapy related toxicities (exclusive of alopecia, neuropathy, and exocrine insufficiency).
16. In the investigator's opinion, histotripsy is not a treatment option for the subject.
17. Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
18. Subject's tumor is not treatable by the System's working ranges (refer to User Guide).

(\*) Subject must not be off chemotherapy \>21 days in total.

Where this trial is running

Barcelona

• Hospital de la Santa Creu i Sant Pau — Barcelona, Spain (RECRUITING)

Study contacts

• Study coordinator: Zoe Secord

Conditions: Pancreas Cancer, Adenocarcinoma of the Pancreas, Pancreatic Cancer, Tumor of Pancreas